Factor VIIa (Activated Factor VII)

09/01/2004 - "Administration of recombinant activated factor VII proved highly effective in management of massive hemorrhage in cardiac surgery."
03/01/2005 - "Some bleeding continued post-operatively: administration of activated Factor VII was associated with a marked reduction in the oozing from his fixator pin-sites and an improvement in his pH from 7.1 to 7.3. "
01/01/2011 - "Despite recombinant activated factor VII promising results in massive bleeding after cardiac surgery, it significantly increases arterial thromboembolic risk. "
01/01/2002 - "In both described patients who were characterized by a high risk of surgical bleeding, the employment of the recombinant activated factor VII led to significant improvement in coagulation system indices and the hemostatic outcome was regarded positive. "
10/01/2012 - "The question addressed was whether recombinant activated factor VII was effective for the treatment of excessive bleeding after paediatric cardiac surgery. "

04/01/2011 - "Platelet binding and activity play important roles in the efficacy of factor VIIa (FVIIa) as a bypassing agent for hemophilia treatment. "
10/26/2001 - "Factor VIIa is also an important therapeutic agent for hemophilia where its function may include TF-independent as well as TF-dependent mechanisms. "
05/01/2013 - "Safety and efficacy of recombinant activated factor VII for long-term secondary prophylaxis in a haemophilia boy with high-titre inhibitors."
08/01/1998 - "[Recombinant activated factor VII: a new treatment for hemophilia]."
10/01/2014 - "Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors."

05/01/2005 - "The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients."
11/01/2009 - "The efficacy of recombinant activated factor VII in severe trauma."
07/01/2011 - "Recombinant activated factor VII safety in trauma patients: results from the CONTROL trial."
08/01/2010 - "Global differences in causes, management, and survival after severe trauma: the recombinant activated factor VII phase 3 trauma trial."
01/01/2014 - "Effects of recombinant activated factor VIIa on abdominal trauma patients."

08/01/2015 - "To conclude, non-surgical bleeds were common and often severe in Glanzmann thrombasthenia; both platelets and recombinant activated factor VII appeared to be effective, and with good safety profiles, for the treatment of non-surgical bleeds. "
07/01/2014 - "Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature."
01/01/2006 - "Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents."
12/01/2005 - "Recombinant activated factor VII is a safe and effective for the treatment and prevention of haemorrhage in haemophiliacs with circulating inhibitors to replacement factors, and patients with Glanzmann's thrombasthenia refractory to platelet transfusion. "
08/01/2006 - "Recombinant activated factor VII is approved for haemophiliacs with inhibitors and patients with thrombasthenia Glanzmann and factor VII deficiency. "

02/01/2014 - "The dose of recombinant activated factor VII, mediastinal drainage, use of blood and blood products, incidence of thrombosis, and 28-day mortality were studied. "
08/01/2012 - "Reprint of: Factor VIIa-AT complex plasma levels and arterial thrombosis."
01/01/2012 - "It is a component of the factor VIIa-TF complex enzyme and plays a primary role in both normal hemostasis and thrombosis. "
12/01/2011 - "Factor VIIa-AT complex plasma levels and arterial thrombosis."
12/01/2011 - "There was no evidence of thrombosis in the first 24 hours after the administration of recombinant activated factor VII. Recombinant activated factor VII treatment reduced blood loss and transfusion requirements and prevented re-exploration in the majority (83.8%) of pediatric cardiac surgery patients. "